C2orf29_D1Bwg0212e Inhibitors
Chemical inhibitors of C2orf29 can exert their inhibitory effects through interference with multiple cellular pathways essential for the proper function of this protein. Alisertib, a known Aurora A kinase inhibitor, can arrest cells at the mitotic entry, indirectly obstructing the function of C2orf29 in cell cycle progression. Similarly, Palbociclib, by targeting CDK4/6, induces a G1 phase arrest, thus halting the cell cycle at a point where C2orf29 is active. Trametinib and Selumetinib, both inhibitors of the MEK1/2 enzymes, disrupt the MEK/ERK pathway which is closely tied to cell proliferation and differentiation, processes where C2orf29 is implicated. This disruption results in the cessation of these processes, thereby functionally inhibiting C2orf29. Venetoclax, as a BCL-2 inhibitor, promotes apoptosis, which reduces the number of cells progressing through the cycle where C2orf29 functions. Bortezomib, by inhibiting proteasome activity, prevents the degradation of cell cycle regulators, thus indirectly inhibiting C2orf29's role in this process.
Continuing with the theme of pathway disruption, Sorafenib impedes the RAF kinase, which is upstream in the RAF/MEK/ERK cascade, a pathway C2orf29 relies on for cell division. Thalidomide, through its effect on the S100 protein, may indirectly influence cell cycle progression, impacting the cellular role of C2orf29. AZD8055, by targeting mTOR kinase, blocks downstream signaling necessary for cell growth and division, impinging upon C2orf29's activity in these pathways. Dasatinib, which inhibits Src family kinases, can arrest pathways regulating cell proliferation, leading to a reduction in C2orf29 activity. Olaparib, as a PARP inhibitor, compromises DNA repair mechanisms, and subsequent cell cycle arrest affects C2orf29's role in cell cycle progression. Lastly, Nutlin-3, by antagonizing MDM2 and stabilizing p53, induces cell cycle arrest, particularly in the G1 phase, thus inhibiting C2orf29's involvement in regulating the cell cycle. Each of these chemicals targets specific cellular mechanisms or pathways that are essential for C2orf29's function, leading to its inhibition.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora A kinase inhibitor. Since Aurora A kinase is essential for mitotic entry, and C2orf29 is involved in cell cycle progression, inhibition of Aurora A kinase by Alisertib could lead to cell cycle arrest, indirectly inhibiting C2orf29 function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor. C2orf29 is required for proper cell cycle progression, and by inhibiting CDK4/6, Palbociclib induces G1 phase arrest, which would result in the functional inhibition of C2orf29 involved in cell cycle regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor, and by inhibiting MEK, it blocks the MEK/ERK pathway, which is crucial for cell proliferation. Inhibition of this pathway would disrupt processes in which C2orf29 is involved, leading to its functional inhibition. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 is a BCL-2 inhibitor. By promoting apoptosis through BCL-2 inhibition, it can decrease the number of cells progressing through the cell cycle, indirectly inhibiting C2orf29, which functions within cell cycle progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By disrupting the degradation of cell cycle regulators, it can interfere with cell cycle progression where C2orf29 has a role, effectively inhibiting its function. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is an inhibitor of MEK1/2. By blocking the MEK/ERK signaling pathway, Selumetinib inhibits cellular proliferation and differentiation processes that C2orf29 is known to be involved in, thus functionally inhibiting C2orf29. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF kinase inhibitor, and by inhibiting RAF, it disrupts the RAF/MEK/ERK signaling cascade, which is critical for cell division. This would inhibit the role of C2orf29 in cell cycle progression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide has been shown to inhibit the expression of S100, which may affect the cell cycle and proliferation. Through these effects, Thalidomide can indirectly inhibit the function of C2orf29 in the cell cycle. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor. By directly inhibiting mTOR, it blocks downstream signaling pathways that are necessary for cell cycle progression and growth, thereby inhibiting C2orf29 activity involved in these processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Since Src kinases can contribute to pathways that regulate cell proliferation, Dasatinib would inhibit those pathways, thereby reducing the functional activity of C2orf29 in cell proliferation. | ||||||